DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis (AAD 2023) - Mar 4, 2023 - Pres time: Mar 18, 2023; 01:20 PM - 01:30 PM; Location: New Orleans Theater B; No abstract available
Clinical • Late-breaking abstract • Dermatology • Immunology • Psoriasis • IL17A
|
|
Richard B Warren, MBChB, PhD
|